A patient receives Enoxaparin at 0800, with no signs of deep vein thrombosis (DVT) later that evening. What is the most likely therapeutic goal of this medication?

Enoxaparin is a low molecular weight heparin (LMWH) used primarily for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The scenario specifies that the patient showed no signs of DVT after administration, which supports its prophylactic use. Enoxaparin functions by enhancing the inhibition of Factor Xa and thrombin, reducing the formation of fibrin clots. It is not used for pain relief, infection control, or inflammation suppression, which are the targets of other drug classes. Thus, the correct rationale is anticoagulation prophylaxis to prevent venous clot formation in at-risk patients.